Table. Baseline Characteristics of Patients With Known Ischemic Heart Disease or Prior Myocardial Infarction From the Copenhagen General Population Study and of Those Eligible for New Medication to Prevent Atherosclerotic Cardiovascular Disease According to Inclusion and Exclusion Criteria Used in 12 Different Trials.
| Characteristicsa | All | Eligibility According to Trial Criteria | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMPROVE-IT | PEGASUS | EMPA-REG | LEADER | SUSTAIN-6 | FOURIER | CANVAS | REVEAL | CANTOS | COMPASS | ODYSSEY | REDUCE-IT | ||
| Ischemic heart disease | |||||||||||||
| Individuals, No. | 6292 | 2004 | 1660 | 811 | 810 | 810 | 1727 | 818 | 845 | 924 | 4176 | 1664 | 977 |
| Sex, male, No. (%) | 3861 (61) | 1423 (71) | 1205 (73) | 559 (69) | 552 (68) | 552 (68) | 1291 (75) | 562 (69) | 689 (82) | 637 (69) | 2682 (63) | 1156 (69) | 743 (76) |
| Age, y | 69 (62-76) | 71 (64-78) | 74 (69-79) | 71 (65-77) | 71 (65-77) | 71 (65-77) | 70 (64-77) | 71 (65-77) | 72 (66-78) | 72 (65-79) | 74 (69-79) | 69 (62-77) | 70 (64-76) |
| Blood pressure, mm Hg | |||||||||||||
| Systolic | 144 (130-158) | 144 (130-158) | 144 (130-160) | 144 (130-158) | 144 (130-158) | 144 (130-158) | 142 (129-156) | 144 (130-158) | 140 (126-154) | 144 (130-159) | 145 (132-160) | 144 (130-159) | 142 (130-157) |
| Diastolic | 82 (75-90) | 81 (74-89) | 80 (72-88) | 80 (71-86) | 80 (71-86) | 80 (71-86) | 80 (73-88) | 80 (71-86) | 79 (71-85) | 80 (72-89) | 80 (73-89) | 82 (75-90) | 80 (73-88) |
| Cholesterol, mg/dL | |||||||||||||
| Total cholesterol | 190 (163-224) | 178 (159-209) | 174 (151-205) | 166 (143-197) | 166 (143-197) | 166 (143-197) | 166 (147-189) | 166 (143-197) | 139 (128-147) | 178 (151-213) | 186 (159-217) | 190 (170-217) | 166 (151-182) |
| HDL cholesterol | 55 (44-69) | 53 (43-66) | 53 (43-66) | 48 (39-61) | 48 (39-61) | 47 (39-61) | 51 (41-64) | 48 (39-61) | 46 (38-56) | 49 (40-63) | 56 (44-70) | 53 (43-66) | 45 (37-56) |
| LDL cholesterol | 101 (76-130) | 93 (74-116) | 86 (67-112) | 77 (61-104) | 77 (60-104) | 77 (60-104) | 81 (66-101) | 77 (61-104) | 62 (50-73) | 93 (70-120) | 93 (72-124) | 101 (85-124) | 74 (62-85) |
| Triglycerides | 137 (96-202) | 139 (96-203) | 139 (97-205) | 168 (112-245) | 169 (112-251) | 169 (112-251) | 139 (97-207) | 168 (112-251) | 124 (89-180) | 153 (112-224) | 136 (96-198) | 142 (100-205) | 210 (175-274) |
| C-reactive protein, mg/L | 1.6 (1.0-2.9) | 1.6 (1.0-3.1) | 1.7 (1.1-3.4) | 1.8 (1.1-3.5) | 1.8 (1.1-3.7) | 1.8 (1.1-3.7) | 1.5 (1.0-2.8) | 1.8 (1.1-3.6) | 1.5 (1.0-3.1) | 3.8 (2.6-5.9) | 1.7 (1.1-3.2) | 1.6 (1.0-3.0) | 1.6 (1.1-2.9) |
| Current smokers, No. (%) | 984 (16) | 364 (18) | 269 (16) | 115 (14) | 113 (14) | 114 (14) | 289 (17) | 118 (14) | 126 (15) | 206 (22) | 593 (14) | 322 (19) | 134 (14) |
| Diabetes, No. (%) | 830 (13) | 274 (14) | 334 (21) | 811 (100) | 810 (100) | 810 (100) | 309 (18) | 818 (100) | 316 (38) | 168 (18) | 747 (17) | 195 (12) | 275 (28) |
| Statin use, No. (%) | 3535 (56) | 1455 (73) | 1245 (75) | 642 (79) | 646 (80) | 646 (80) | 1727 (100) | 648 (79) | 785 (93) | 629 (68) | 2633 (62) | 1097 (66) | 977 (100) |
| Myocardial Infarction | |||||||||||||
| Individuals, No. | 2277 | 2004 | 1660 | 332 | 334 | 334 | 1624 | 334 | 629 | 924 | 1608 | 1664 | 474 |
| Sex, male, No. (%) | 1637 (72) | 1423 (71) | 1205 (73) | 256 (77) | 255 (76) | 255 (76) | 1221 (75) | 257 (77) | 528 (84) | 637 (69) | 1189 (73) | 1156 (69) | 387 (82) |
| Age, y | 70 (63-77) | 71 (64-78) | 74 (69-79) | 71 (66-76) | 71 (66-77) | 71 (66-77) | 70 (63-77) | 71 (66-76) | 72 (66-78) | 72 (65-79) | 74 (69-79) | 69 (62-77) | 70 (63-76) |
| Blood pressure, mm Hg | |||||||||||||
| Systolic | 142 (130-157) | 144 (130-158) | 144 (130-160) | 144 (130-156) | 144 (130-156) | 144 (130-156) | 142 (129-156) | 144 (130-156) | 140 (125-152) | 144 (130-159) | 144 (130-160) | 144 (130-159) | 141 (130-156) |
| Diastolic | 80 (73-89) | 81 (74-89) | 80 (72-88) | 79 (70-86) | 79 (70-86) | 79 (70-86) | 80 (73-88) | 79 (70-86) | 79 (70-85) | 80 (72-89) | 80 (72-88) | 82 (75-90) | 80 (72-88) |
| Cholesterol, mg/dL | |||||||||||||
| Total cholesterol | 174 (151-209) | 178 (159-209) | 174 (151-205) | 163 (143-190) | 163 (139-190) | 163 (139-190) | 166 (147-190) | 163 (143-190) | 139 (128-147) | 178 (151-213) | 174 (151-205) | 190 (170-217) | 163 (147-178) |
| HDL cholesterol | 52 (42-65) | 53 (43-66) | 53 (43-66) | 47 (38-59) | 46 (38-59) | 46 (38-59) | 51 (41-63) | 46 (38-59) | 46 (38-59) | 49 (40-63) | 53 (42-66) | 53 (43-66) | 44 (36-54) |
| LDL cholesterol | 89 (70-116) | 93 (74-116) | 86 (67-112) | 76 (58-102) | 75 (58-101) | 76 (58-101) | 81 (66-101) | 76 (58-102) | 63 (51-73) | 93 (70-120) | 85 (67-112) | 101 (85-124) | 74 (62-85) |
| Triglycerides | 140 (97-206) | 139 (96-203) | 139 (97-205) | 174 (118-245) | 174 (118-248) | 174 (118-248) | 140 (97-207) | 174 (118-249) | 121 (89-174) | 153 (112-224) | 139 (97-204) | 142 (100-205) | 214 (177-277) |
| C-reactive protein, mg/L | 1.6 (1.0-3.0) | 1.6 (1.0-3.1) | 1.7 (1.1-3.4) | 1.9 (1.1-3.9) | 1.9 (1.1-3.9) | 1.9 (1.1-3.9) | 1.5 (1.0-2.7) | 1.9 (1.1-3.9) | 1.5 (1.0-3.1) | 3.8 (2.6-5.9) | 1.7 (1.1-3.3) | 1.6 (1.0-3.0) | 1.7 (1.1-3.0) |
| Current smokers, No. (%) | 412 (18) | 364 (18) | 269 (16) | 63 (19) | 62 (19) | 62 (19) | 278 (17) | 64 (19) | 107 (17) | 206 (22) | 276 (17) | 322 (19) | 80 (17) |
| Diabetes, No. (%) | 338 (15) | 274 (14) | 334 (21) | 330 (100) | 334 (100) | 334 (100) | 284 (17) | 334 (100) | 133 (21) | 168 (18) | 308 (21) | 195 (12) | 119 (25) |
| Statin use, No. (%) | 1671 (74) | 1455 (73) | 1245 (75) | 284 (86) | 287 (86) | 287 (86) | 1624 (100) | 286 (86) | 591 (94) | 629 (68) | 1228 (75) | 1097 (66) | 474 (100) |
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
SI conversion factors: To convert HDL and LDL cholesterol to mmol/L, multiply by 0.0259; C-reactive protein to nmol/L, multiply by 9.524; triglycerides to mmol/L, multiply by 0.0113.
a
Baseline characteristics are presented as proportions for categorical variables and as medians (interquartile range) for continuous variables.